Evidence map›Paper›PMID 41982663›Full record

ReviewFrontiers in pharmacology2026

Dual-pathway mechanisms of plant-derived polysaccharides in ulcerative colitis: integrative roles of microbiota modulation, immune regulation, and barrier restoration.

Yang Wenying

Abstract readReview
In one paragraph

Review in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Yang WenyingCollege of Bioscience and Biotechnology, Hunan Agricultural University, Changsha, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic inflammation of the colon has been described as an inflammatory condition of the colon that is characterized by recurring flare-ups of the disease (ulcerative colitis). Ulcerative colitis is a complex inflammatory disorder of the colon that is determined by the combination of several mechanisms: abnormal bacterial flora, inappropriate immune response, and the breakdown of the protective lining of the colon. The last 10 years have seen the emergence of plant derived polysaccharides as new biological active compounds with the potential to intervene at the different levels of the disease. Plant derived polysaccharides can be divided into two separate regulatory modes; the first mode of action occurs when the polysaccharides work in collaboration with the microbiota to modify the structure of the microbiota and create a positive environment for the growth of the beneficial bacteria. The second mode of action occurs without the use of the microbiota and works by creating anti-inflammatory signals to regulate the body's immune system and protect the integrity of the intestinal lining. The authors of this paper used a systematic method to identify 103 papers published on the subject of plant derived polysaccharides and their effects on the disease mechanism of ulcerative colitis. The results of the analysis of these papers indicated that the polysaccharides act to reduce the inflammatory process through the downregulation of the three major inflammatory signaling pathways of NF-κB, PI3K/AKT, and JAK/STAT. In addition, the polysaccharides were shown to restore the balance of macrophages and T-cells and increase the production of mucus producing cells and tighten the tight junctions between the intestinal epithelial cells. In recent studies it was found that the metabolic products of the microbes and the intracellular signaling processes are part of a coordinated regulatory network. Therefore, based on the results of the study, plant derived polysaccharides appear to be multi-target modulators of the disease process rather than just acting on one pathway of the disease process. Although the study indicates that there has been significant progress in understanding how the plant derived polysaccharides interact with the disease process, there are still many barriers to overcome before the plant derived polysaccharides can be used as a treatment for ulcerative colitis in humans. These barriers include; the structural heterogeneity of the polysaccharides, the lack of clinical trials evaluating the safety and efficacy of the polysaccharides as a treatment for ulcerative colitis, and the large variation in how individuals respond to changes in the composition of the gastrointestinal tract microbiota. Therefore, this study represents a comprehensive review of the current state of knowledge on the interaction of plant derived polysaccharides with the pathophysiology of ulcerative colitis, and highlights areas of future research necessary to develop polysaccharide based treatments for ulcerative colitis that are safe, effective, and can be translated into the clinic.

Indexed as

anti-inflammatory signallingepithelial barrier repairgut microbiotaplant-derived polysaccharidesshort-chainfatty acidsulcerative colitis

Identifiers

PMID41982663
PMCPMC13071011

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.